Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019163 (
hepatitis B
)
38,309
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Selenium binding protein 1
(
SELENBP1
) has been known to be reduced in various types cancer, and epigenetic change is shown to be likely to account for the reduction of
SELNEBP1
expression. With cDNA microarray comparative analysis, we found that
SELENBP1
is markedly decreased in
hepatitis B
virus-X (HBx)-expressing cells. To clarify the effect of HBx on
SELENBP1
expression, we compared the expression levels of
SELENBP1
mRNA and protein by semi-quantitative RT-PCR, Northern blot, and Western blot. As expected,
SELENBP1
expression was shown to be reduced in cells expressing HBx, and reporter gene analysis showed that the
SELENBP1
promoter is repressed by HBx. In addition, the stepwise deletion of 5' flanking promoter sequences resulted in a gradual decrease in basal promoter activity and inhibition of
SELENBP1
expression by HBx. Moreover, immunohistochemistry on tissue microarrays containing 60 pairs of human liver tissue showed decreased intensity of
SELENBP1
in tumor tissues as compared with their matched non-tumor liver tissues. Taken together, our findings suggest that inhibition of
SELENBP1
expression by HBx might act as one of the causes in the development of hepatocellular carcinoma caused by HBV infection.
...
PMID:Hepatitis B Virus-X Downregulates Expression of Selenium Binding Protein 1. 3244 34
